ArticleClinical cancer research : an official journal of the American Association for Cancer Research2024

FDA Approval Summary: Asciminib for Ph+ CML in Chronic Phase Treated with Two or More Tyrosine Kinase Inhibitors and for the T315I Mutation.

Gulsum E Pamuk et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.